The FDA grants Synageva BioPharma (GEVA) Breakthrough Therapy designation for sebelipase alfa, a...

|About: Synageva BioPharma Corp. (GEVA)|By:, SA News Editor

The FDA grants Synageva BioPharma (GEVA) Breakthrough Therapy designation for sebelipase alfa, a treatment for early onset acid lipase deficiency. Earlier this month, JPMorgan expressed some skepticism based on what the bank says is a fairly low level of disease awareness (even among specialists). (PR)